

Output measures		Target 20/2	1 Actual		Commentary
1.1 Timeliness of funding decisions - As measured by the average time to rank new applications		Downward tre	end		This measure is under development and an updated will be provided our next quarterly report.
4.2 Timeliness of Exceptional Circumstances Decisions - As measured by the percentage of decisions made within target of 10 working days	50%	Upward trend from 50% ctual	37%		We experienced high volumes of NPPA requests during July and Augu but a concerted effort by staff (along with additional resource) meant that by the end of September we had resolved the backlog of applications. High priority applications were prioritised but some lower
	0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020				priority applications were resolved outside of the 10 working day target. Volumes appear to be returning to normal and we expect to s see an upward trend over the full year. We are keeping a watching be on this.
4.3 Timeliness of PTAC and sub committee records - As measured by the average time to publish records Note: cumulative measure	100 See days 50 Actu	Downward tre	end 50 days	•	Performance is on track. Following process improvement work undertaken in 2019, our timeliness has continued to improve. There have also been efficiencies gained during Covid-19 as we trial using o committees in new and different ways.
	0 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020				
trategic Priority measures		Target 20/2	1 Actual		Commentary
ata and Analytics 3.1 Usage of visual analytics tool - s measured by the implementation of new IT capability hich will enable PHARMAC to interactively and ynamically present data visually	Sessions initiated in last 30 days 195 Number of business users* 12 Major Apps available or under development 4 * excludes developers (ie Analysts)			•	Over the last quarter we have identified many areas of the business that will benefit from accessing this tool and we are on track for implementing this as a capability in PHARMAC. 12 users have been trained over the last quarter and the visual analytics tool was access 195 times during the month of September. 4 dashboards are under development or at testing phase, including a dashboard that (over ti will capture our external performance measures to streamline interr data collection processes.
ublic Understanding, Trust and Confidence 9.1 Increased website traffic and engagement - s measured by the number of unique visits to the HARMAC website and the Number of bounce backs risitors that leave the website after viewing only one page)		Unique visits trend up Bounce backs trend down			PHARMAC launched a new website on 20 October. We will be able to report progress in our next quarterly report using data from our new website.
ublic Understanding, Trust and Confidence 9.3 Improved media sentiment - s measured by the net positive media monitoring score	10 5 0	Upward trend —Actual	0.1		This is a new measure and baseline is being established. The scores range from -10 (very negative), 0 (balance or neutral) to +10 (very positive). Our media impact score for the first quarter of 2020/21 wa 0.1 which is slightly above neutral. A total of 704 media reports were analysed that mentioned PHARMAC with 35% of this coverage positi in tone. The leading message of the coverage was "PHARMAC does need the medicines New Zealanders want or need". This was the theories of 124 of the media reports.
Organisational Excellence measure		Target 20/2	1 Actual		Commentary
14.1 Percentage of up-time (availability) of PHARMAC's key operating systems (quarterly)	95%	99% Actual	100%		No outages for our key operating systems occurred last quarter.
	90% Q3 Q4 Q1 Q2 Q3 Q4	· Target			